Van t Hof AWJ, ten Berg JM, Heestermans T, et al. Prehospital ini- tiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multi-centre, double- blind, randomised controlled trial. Lancet. 2008;372:537 46. 609. ten Berg JM, van t Hof AWJ, Dill T, et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol. 2010;55:2446 55. 610. Ellis SG, Tendera M, de Belder MA, et al. 1-year survival in a ran- domized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. J Am Coll Cardiol Intv. 2009;2:909 16. 611. Ellis SG, Tendera M, de Belder MA, et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358: 2205 17. 612. El Khoury C, Dubien PY, Mercier C, et al. Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study. Arch Cardiovasc Dis. 2010;103:285 92. Levine et al 2011 ACCF/AHA/SCAI PCI Guideline e635 613. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascu- larization. N Engl J Med. 1997;336:1689 96. 614. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syn- dromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999; 100:2045 8. 615. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med. 1999;340:1623 9. 616. Kastrati A, Mehilli J, Neumann FJ, et al. 